Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 2/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.61 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.55 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14532997 | 1.00 | AHCY (0.69) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL13777726 | 1.00 | AHCY (0.69) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL2749577 | 1.00 | AHCY (0.69) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL13296262 | 1.00 | AHCY (0.69) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL10459063 | 0.91 | ADORA2A (0.69) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL15462103 | 0.87 | ADORA3 (0.77) | AHCYADORA3HSP90B1ADORA2AADORA2B | |
| SCHEMBL19423461 | 0.87 | ADORA3 (0.77) | AHCYADORA3HSP90B1ADORA2AADORA2B | |
| SCHEMBL12359604 | 0.86 | ADORA2A (0.57) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL30712751 | 0.86 | AHCY (0.69) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL9404167 | 0.86 | AHCY (0.69) | AHCYHIF1ATMEM97SIGMAR1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158604-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-7737127-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
| EP-1496911-B1 | USE OF A COMBINATION COMPRISING A2A ADENOSINE RECEPTOR AGONISTS AND ANTI-PATHOGENIC AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIV VIRGINIA (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070265440-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY RESPONSE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-11-15 | — | — | US | disclosed |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-04 | — | — | US | disclosed |
| US-7226913-B2 | Pharmaceutical compositions having A2A adenosine receptor agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-06-05 | — | — | US | disclosed |
| US-7214665-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1194440-B1 | INDUCTION OF PHARMACOLOGICAL STRESS WITH ADENOSINE RECEPTOR AGONISTS | UNIV VIRGINIA (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20030162742-A1 | Methods and compositions for treating inflammatory response | UNIVERSITY OF VIRGINIA PATENT FOUNDATION, UNIVERSITY OF VIRGINIA. | 2003-08-28 | — | — | US | disclosed |
| WO-2003029264-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-04-10 | — | — | WO | disclosed |
| US-6531457-B2 | A2A adenosine receptor antagonists such as methyl-4-(3-(9-(5-(N-ethylcarbamoyl)-3,4-dihydrooxolan-2-yl)-6-aminopurin-2 -yl))prop-2-ynyl)cyclohexane-carboxylate | UNIVERSITY OF VIRGINIA | 2003-03-11 | — | — | US | disclosed |
| EP-1194440-A2 | INDUCTION OF PHARMACOLOGICAL STRESS WITH ADENOSINE RECEPTOR AGONISTS | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6322771-B1 | PARENTERALLY ADMINISTERING TO A MAMMAL A PURINE DERIVATIVE TO DIAGNOSE CORONARY ARTERY STENOSIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2001-11-27 | — | — | US | disclosed |
| EP-1150991-A2 | COMPOSITIONS FOR TREATING INFLAMMATORY RESPONSE | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2001-11-07 | — | — | EP | disclosed |
| US-20010027185-A1 | Methods and compositions for treating inflammatory response | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2001-10-04 | — | — | US | disclosed |
| US-6232297-B1 | ADMINISTERING 4-AMINOPYRROLO(3,2-D)PYRIMIDINE DERIVATIVE AS ADENOSINE RECEPTOR ANTAGONIST | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2001-05-15 | — | — | US | disclosed |
| WO-2000078774-A2 | INDUCTION OF PHARMACOLOGICAL STRESS WITH ADENOSINE RECEPTOR AGONISTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000044763-A2 | COMPOSITIONS FOR TREATING INFLAMMATORY RESPONSE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265440-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY RESPONSE | ADORA2A, ADORA2B, LTB4R2 | AHCY 288/4885HIF1A 666/4885TMEM97 2436/4885 |
| US-20030162742-A1 | Methods and compositions for treating inflammatory response | ADORA2A, P2RY2, LTB4R2 | AHCY 303/4885HIF1A 546/4885TMEM97 1673/4885 |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | AHCY 1348/4885HIF1A 1116/4885TMEM97 1388/4885 |
| US-20010027185-A1 | Methods and compositions for treating inflammatory response | LTB4R2, ADORA2A, PTGES2 | AHCY 389/4885HIF1A 312/4885TMEM97 2664/4885 |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | AHCY 887/4885HIF1A 1685/4885TMEM97 477/4885 |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | AHCY 887/4885HIF1A 1685/4885TMEM97 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.